

# **WEEKLY EPIDEMIOLOGICAL REPORT**

## A publication of the Epidemiology Unit Ministry of Health

231, de Saram Place, Colombo 01000, Sri Lanka Tele: + 94 11 2695112, Fax: +94 11 2696583, E mail: epidunit@sltnet.lk Epidemiologist: +94 11 2681548, E mail: chepid@sltnet.lk Web: http://www.epid.gov.lk

### Vol. 42 No. 06

## 31<sup>st</sup> – 06<sup>th</sup> February 2015

## Antimicrobial Resistance- (Part II)

This is the last of the series of two article on antimicrobial resistance.

#### **Present situation**

#### Resistance in bacteria

WHO's 2014 report on global surveillance of antimicrobial resistance reveals that antibiotic resistance is no longer a prediction for the future; it is happening right now, across the world, and is putting at risk the ability to treat common infections in the community and hospitals. Without urgent, coordinated action, the world is heading towards a post-antibiotic era, in which common infections and minor injuries, which have been treatable for decades, can once again kill.

- Treatment failure to the drug of last resort for gonorrhoea – third-generation cephalosporins

   has been confirmed in several countries.
   Untreatable gonococcal infections result in increased rates of illness and complications, such as infertility, adverse pregnancy outcomes and neonatal blindness, and has the potential to reverse the gains made in the control of this sexually transmitted infection.
- Resistance to one of the most widely used antibacterial drugs for the oral treatment of urinary tract infections caused by *E. coli* – fluoroquinolones – is very widespread.
- Resistance to first-line drugs to treat infections caused by *Staphlylococcus aureus* – a common cause of severe infections acquired both

- in health-care facilities and in the community is also widespread.
- Resistance to the treatment of last resort for life-threatening infections caused by common intestinal bacteria – carbapenem antibiotics – has spread to all regions of the world. Key tools to tackle antibiotic resistance – such as basic systems to track and monitor the problem – reveal considerable gaps. In many countries, they do not even seem to exist.

# What accelerates the emergence and spread of antimicrobial resistance?

The development of AMR is a natural phenomenon. However, certain human actions accelerate the emergence and spread of AMR. The inappropriate use of antimicrobial drugs, including in animal husbandry, favours the emergence and selection of resistant strains, and poor infection prevention and control practices contribute to further emergence and spread of AMR.

#### Need for concerted actions

AMR is a complex problem driven by many interconnected factors. As such, single, isolated interventions have little impact. Coordinated action is required to minimize emergence and spread of AMR.

People can help tackle resistance by:

 using antibiotics only when they are prescribed by a certified health professional;

Contents	Page
<ol> <li>Leading Article – Antimicrobial Resistance—(Part II)</li> <li>Summary of selected notifiable diseases reported - (24<sup>th</sup> – 30<sup>th</sup> January 2015)</li> <li>Surveillance of vaccine preventable diseases &amp; AFP - (24<sup>th</sup> – 30<sup>th</sup> January 2015)</li> </ol>	1 3 4

## WER Sri Lanka - Vol. 42 No. 06

- completing the full treatment course, even if they feel better;
- never sharing antibiotics with others or using leftover prescriptions.
- Health workers and pharmacists can help tackle resistanceby:
- enhancing infection prevention and control
- prescribing and dispensing antibiotics only when they are truly needed
- prescribing and dispensing the right antibiotic(s) to treat the illness

Policymakers can help tackle resistance by:

- strengthening resistance tracking and laboratory capacity
- strengthening infection control and prevention
- regulating and promoting appropriate use of medicines
- promoting cooperation and information sharing among all stakeholders.

**Policymakers, scientists and industry** can help tackle resistance by:

 fostering innovation and research and development of new vaccines, diagnostics, infection treatment options and other tools.

#### WHO's response

WHO is working in collaboration with partners across many sectors to identify strategies and actions to mitigate AMR. WHO is already working closely with the World Organization for Animal Health (OIE) and the Food and Agriculture Organization of the United Nations (FAO) to promote best practices to avoid the emergence and spread of antibacterial resistance, including optimal use of antibiotics in both humans and animals.

In 2011, the theme of World Health Day was "Antimicrobial resistance: no action today, no cure tomorrow", and a six-point policy package was published to assist countries with tools to combat antimicrobial resistance.

In 2014, WHO published its first global report on surveillance of antimicrobial resistance, with data provided by 114 countries.

WHO is guiding the response to AMR by:

 bringing all stakeholders together to agree on and work towards a coordinated response

- strengthening national stewardship and plans to tackle AMR
- generating policy guidance and providing technical support for Member States
- actively encouraging innovation, research and development.

#### Status of resistance in South east Asia Region

No systemic studies have been done in this region to understand the status of resistance, trends and consumption of antimicrobial agents. While multidrug resistance in Mycobacterium Tuberculosis, because of well performing national TB control Programmes in the region, is still at an acceptable low level of <3%, this figure is very high among several other bacteria.

#### Health and economic burden due to ABR

Evidence related to the health and economic burden due to ABR in infections caused by *E. coli, K. pneumoniae* and MRSA was examined through systematic reviews of the scientific literature. Patients with infections caused by bacteria resistant to a specific antibacterial drug generally have an increased risk of worse clinical outcomes and death, and consume more healthcare resources, than patients infected with the same bacteria not demonstrating the resistance pattern in question. Available data are insufficient to estimate the wider societal impact and economic implications when effective treatment for an infection is completely lost as a result of resistance to all available drugs.

#### Sources

WHO-antimicrobial resistance global report on surveillance, available at <u>http://www.who.int/mediacentre/factsheets/fs194/en/</u>

Compiled by Dr. C U D Gunasekara of the epidemiology unit.

## 31st February 06th 2015

## WER Sri Lanka - Vol. 42 No. 06

## Table 1: Selected notifiable diseases reported by Medical Officers of Health

31st February 06th 2015

able	1:	Sel	ect	ed n	otif	iable	e di	seas	ses	rep	orte	ed b	y M	edi	cal	Off	icer	s of	He	alth		<b>24</b> <sup>th</sup>	- 30	th J	an	201	5 (0	5 <sup>th</sup>
<u>i</u>	** ت	31	60	46	6	38	46	25	25	0	0	75	40	25	20	50	57	50	48	69	68	43	65	45	39	27	62	40
WKCD	*⊢	69	40	54	91	62	54	75	75	100	100	25	60	75	80	50	43	50	52	31	32	57	35	55	61	73	38	60
Leishma- niasis	в	0	0	0	1	0	0	0	21	7	0	0	0	0	1	0	0	0	ω	0	18	4	0	ъ	m	0	0	68
Leishn niasis	۲	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0	2	1	0	-1	0	0	0	∞
Meningitis	B	m	2	ഹ	2	H	4	10	1	7	1	0	0	0	1	2	m	0	m	1	5	9	~		m	9	0	74
Men	A	0	0		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1				0	0	0	9
Chickenpox	8	36	11	19	26	7	ч	29	5	31	15	0	0	1	0	4	16	4	29	4	12	13	12	6	4	18	17	317
Chic	A	12	5	ω	7	0	0	6		5	0	0	0	0	0	1	0		9	0	0	н	2	2	0	6	4	70
Human Rabies	ß	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Hu Ral	A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Viral Hepatitis	B	9	17	ம	33		20	1	9	9	ε	0	0	0	0	0	0	0	~	0	2		6	m	33	15	0	168
	A		2	1	9	0	0	0		e	0	0	0	0	0	0	0	0	0	0	0	0		0	2	0	0	17
Typhus Fever	æ		1	0	12	H	2	9	4	4	256	ω	2	7		0	0		~	2	m	0	6	10	ø	2	0	345
Typh	A		0	0	ч	0	0		0		41	0		0	0	0	0			0	0	0		4		0	0	5
Leptospirosi s	8	20	30	41	6	12	4	30	15	19	5	0	2	8	2	Η	0	4	45	9	52	26	2	20	35	32		451
	A	2	ε	m	2	ч	0	2		1	1	0	0	2	0	0	0	0	13	0	0	H		2		4	0	<b>4</b>
Food Poisoning	8	7	2	m	0	0	0	4	0	19	ε	2	ч	1	1	0	0	22	0	0	2	0	0	-	ч	0	ß	74
	A	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	M
Enteric Fever	B	2	2	9	ъ	H	m	0	Μ	2	54	2	Μ	5		1	0	ы	2	0	0	0	ч	m	4	15	0	123
	A	2	0	1	0	0		0	0	-1	6	0	0	0	0	0	0		0	0	0	0	0	0	0	1	0	16
Encephalit is	8		2	1	0	0	0	0	0	0	e	0	0	2	0	н	0	0		0	0	0	0	0	7	2	0	15
	A	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Dysentery	8	22	9	ъ	25	S	28	13	2	8	98	10		4	ъ	17	12	2	23	8	7	9	19	21	39	6	16	402
	A	m	1	0	m	0	4	2		2	19	0	0	0	0	1	0	0	4	0	0	0		ъ	0	m	1	50
Dengue Fever	æ	1736	630	270	250	163	30	145	45	81	614	14	50	32	35	272	6	121	283	222	102	43	186	42	138	101	209	5823
Deng	۷	410	46	29	42	20	m	31	10	17	56	2	4	11	ъ	55	0	30	41	11	2	m	2	m	15	13	18	884
RDHS Division		Colombo	Gampaha	Kalutara	Kandy	Matale	NuwaraEliya	Galle	Hambantota	Matara	Jaffna	Kilinochchi	Mannar	Vavuniya	Mullaitivu	Batticaloa	Ampara	Trincomalee	Kurunegala	Puttalam	Anuradhapura	Polonnaruwa	Badulla	Monaragala	Ratnapura	Kegalle	Kalmune	SRILANKA

## 31st February 06th 2015

### Table 2: Vaccine-Preventable Diseases & AFP

### 24th - 30th Jan 2015 (05th Week)

Disease			N	o. of Cas	es by P	rovince			Number of cases during current	Number of cases during same	Total number of cases to date in	Total num- ber of cases to date in	Difference between the number of cases to date	
	w	С	S	N	E	NW	NC	U	Sab	week in 2015	week in 2014	2015	2014	in 2014& 2015
AFP*	00	00	00	00	00	00	00	00	00	00	04	06	08	-25%
Diphtheria	00	00	00	00	00	00	00	00	00	00	00	00	00	%
Mumps	00	02	00	02	01	01	00	02	00	08	11	36	94	-61.7%
Measles	08	00	01	00	00	00	02	01	04	16	61	131	440	-70.2%
Rubella	00	00	00	00	00	00	00	00	00	00	00	02	00	%
CRS**	00	00	00	00	00	00	00	00	00	00	00	00	00	%
Tetanus	00	00	00	00	00	00	00	00	00	00	01	01	02	-50%
Neonatal Teta- nus	00	00	00	00	00	00	00	00	00	00	00	00	00	%
Japanese En- cephalitis	00	00	00	00	00	00	00	00	00	00	01	02	09	-77.8%
Whooping Cough	00	00	00	01	00	00	00	00	00	01	03	09	07	+28.6%
Tuberculosis	56	18	20	18	13	12	19	03	27	186	174	981	1120	-12.4%

#### Key to Table 1 & 2

Provinces: W: Western, C: Central, S: Southern, N: North, E: East, NC: North Central, NW: North Western, U: Uva, Sab: Sabaragamuwa.

RDHS Divisions: CB: Colombo, GM: Gampaha, KL: Kalutara, KD: Kandy, ML: Matale, NE: Nuwara Eliya, GL: Galle, HB: Hambantota, MT: Matara, JF: Jaffna,

KN: Killinochchi, MN: Mannar, VA: Vavuniya, MU: Mullaitivu, BT: Batticaloa, AM: Ampara, TR: Trincomalee, KM: Kalmunai, KR: Kurunegala, PU: Puttalam, AP: Anuradhapura, PO: Polonnaruwa, BD: Badulla, MO: Moneragala, RP: Ratnapura, KG: Kegalle.

Data Sources:

Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Neonatal Tetanus, Whooping Cough, Chickenpox, Meningitis, Mumps., Rubella, CRS, Special Surveillance: AFP\* (Acute Flaccid Paralysis), Japanese Encephalitis

CRS\*\* =Congenital Rubella Syndrome

AFP and all clinically confirmed Vaccine Preventable Diseases except Tuberculosis and Mumps should be investigated by the MOH

## **Dengue Prevention and Control Health Messages**

Look for plants such as bamboo, bohemia, rampe and banana in your surroundings and maintain them

#### PRINTING OF THIS PUBLICATION IS FUNDED BY THE WORLD HEALTH ORGANIZATION (WHO).

Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@sltnet.lk. Prior approval should be obtained from the Epidemiology Unit before publishing data in this publication

## **ON STATE SERVICE**

Dr. P. PALIHAWADANA CHIEF EPIDEMIOLOGIST EPIDEMIOLOGY UNIT 231, DE SARAM PLACE COLOMBO 10